IPO, check: Now, ADC Therapeutics files for lonca approval

ADC Therapeutics nearly went through the entire alphabet before trying, twice, to get off an IPO. Now, that's done, and it’s looking to become a commercial biotech.

Today, the Swiss company said it has sent off a biologics license application (BLA) to the FDA for loncastuximab tesirine, nicknamed “lonca,” an antibody-drug conjugate targeting CD19 in patients with relapsed diffuse large B-cell lymphoma (DLBCL).